These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 31472218

  • 21. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
    Khanfar M, Al-Remawi M, Al-Akayleh F, Hmouze S.
    AAPS PharmSciTech; 2021 Mar 21; 22(3):112. PubMed ID: 33748914
    [Abstract] [Full Text] [Related]

  • 22. Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
    Metre S, Mukesh S, Samal SK, Chand M, Sangamwar AT.
    Mol Pharm; 2018 Feb 05; 15(2):652-668. PubMed ID: 29287144
    [Abstract] [Full Text] [Related]

  • 23. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT, DeClerck L, Löbmann K, Grohganz H, Rades T, Laitinen R.
    Pharmazie; 2015 Jul 05; 70(7):452-7. PubMed ID: 26373205
    [Abstract] [Full Text] [Related]

  • 24. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.
    Biopharm Drug Dispos; 2012 Sep 05; 33(6):304-15. PubMed ID: 22847220
    [Abstract] [Full Text] [Related]

  • 25. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate.
    Higashi K, Hayashi H, Yamamoto K, Moribe K.
    Int J Pharm; 2015 Oct 15; 494(1):9-16. PubMed ID: 26253374
    [Abstract] [Full Text] [Related]

  • 26. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions.
    Löbmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R.
    Eur J Pharm Biopharm; 2012 May 15; 81(1):159-69. PubMed ID: 22353489
    [Abstract] [Full Text] [Related]

  • 27. Hot Melt Extrusion and Spray Drying of Co-amorphous Indomethacin-Arginine With Polymers.
    Lenz E, Löbmann K, Rades T, Knop K, Kleinebudde P.
    J Pharm Sci; 2017 Jan 15; 106(1):302-312. PubMed ID: 27817830
    [Abstract] [Full Text] [Related]

  • 28. Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
    Craye G, Löbmann K, Grohganz H, Rades T, Laitinen R.
    Molecules; 2015 Dec 03; 20(12):21532-48. PubMed ID: 26633346
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
    Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S.
    J Pharm Pharm Sci; 2010 Dec 03; 13(4):589-606. PubMed ID: 21486533
    [Abstract] [Full Text] [Related]

  • 30. Aspartame as a co-former in co-amorphous systems.
    Wu W, Löbmann K, Schnitzkewitz J, Knuhtsen A, Pedersen DS, Grohganz H, Rades T.
    Int J Pharm; 2018 Oct 05; 549(1-2):380-387. PubMed ID: 30075253
    [Abstract] [Full Text] [Related]

  • 31. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
    Wu W, Grohganz H, Rades T, Löbmann K.
    Eur J Pharm Sci; 2021 Jan 01; 156():105582. PubMed ID: 33039568
    [Abstract] [Full Text] [Related]

  • 32. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
    Ojarinta R, Saarinen J, Strachan CJ, Korhonen O, Laitinen R.
    Eur J Pharm Biopharm; 2018 Nov 01; 132():112-126. PubMed ID: 30248394
    [Abstract] [Full Text] [Related]

  • 33. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G, Löbmann K, Grohganz H, Rades T.
    Int J Pharm; 2019 Feb 25; 557():366-373. PubMed ID: 30578980
    [Abstract] [Full Text] [Related]

  • 34. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov 25; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 35. Mechanistic elucidation of formation of drug-rich amorphous nanodroplets by dissolution of the solid dispersion formulation.
    Ueda K, Higashi K, Moribe K.
    Int J Pharm; 2019 Apr 20; 561():82-92. PubMed ID: 30822504
    [Abstract] [Full Text] [Related]

  • 36. Role of P-glycoprotein in deoxynivalenol-mediated in vitro toxicity.
    Ivanova L, Fæste CK, Solhaug A.
    Toxicol Lett; 2018 Mar 01; 284():21-28. PubMed ID: 29174985
    [Abstract] [Full Text] [Related]

  • 37. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
    Mesallati H, Conroy D, Hudson S, Tajber L.
    Eur J Pharm Biopharm; 2017 Dec 01; 121():73-89. PubMed ID: 28919470
    [Abstract] [Full Text] [Related]

  • 38. Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin.
    Wei Y, Zhou S, Hao T, Zhang J, Gao Y, Qian S.
    Eur J Pharm Sci; 2019 Mar 01; 129():21-30. PubMed ID: 30590119
    [Abstract] [Full Text] [Related]

  • 39. Preparation and physicochemical characterization of binary and ternary ground mixtures of carvedilol with PVP and SLS aimed to improve the drug dissolution.
    Bolourchian N, Talamkhani Z, Nokhodchi A.
    Pharm Dev Technol; 2019 Nov 01; 24(9):1115-1124. PubMed ID: 31282827
    [Abstract] [Full Text] [Related]

  • 40. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.
    Jensen KT, Löbmann K, Rades T, Grohganz H.
    Pharmaceutics; 2014 Jul 14; 6(3):416-35. PubMed ID: 25025400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.